PTCT compared with MDGL: revenue, margins and what each company keeps, and the suppliers and customers both name

PTCTPTC Therapeutics, Inc.

Mkt capRevenueRevenue

MDGLMadrigal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

PTCTPTC Therapeutics, Inc.

MDGLMadrigal Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PTCT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Oct 30 '26±12.0%▼−6.97%×0.58

Q2 FY26±11.6%▼−9.94%×0.85

Q1 FY26±9.4%▲+14.27%×1.52

Feb 20 '26±4.3%▲+1.09%×0.26

MDGL

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±10.5%▼−9.83%×0.93

Q1 FY26±9.2%▲+7.42%×0.80

= impliedPTCT realized, solidMDGL realized, hatchedOne scale, both sides: full bar = 15%× = |realized| ÷ impliedSource: market data

Feb 19 '26

±6.2%

▼−11.11%

×1.79

Nov 4 '25±12.9%▲+7.83%×0.60

PTCTPTC Therapeutics, Inc.

59.94▼−7.01%· post 59.99

Mkt cap$5.0BRevenue$361MQ2 FY26Revenue$1.7BFY25

MDGLMadrigal Pharmaceuticals, Inc.

430.17▼−0.35%· post 433.06

ClosedOct 30 '26

Mkt cap$9.9BRevenue$364MQ2 FY26Revenue$958MFY25

Compare

ClosedOct 30 '26

PTCTPTC Therapeutics, Inc.

MDGLMadrigal Pharmaceuticals, Inc.

59.94▼−7.01%post 59.99

Price

430.17▼−0.35%post 433.06

$5.0B

Mkt cap

$9.9B

Q2 FY26$361M

Revenue

$364MQ2 FY26

FY25$1.7B

Revenue

$958MFY25

PTCT59.94▼−7.01%vsMDGL430.17▼−0.35%ClosedOct 30 '26